nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—psoriatic arthritis—Crohn's disease	0.179	0.362	CtDrD
Methotrexate—colon cancer—Crohn's disease	0.168	0.34	CtDrD
Methotrexate—ankylosing spondylitis—Crohn's disease	0.147	0.298	CtDrD
Methotrexate—SLC46A1—Sulfasalazine—Crohn's disease	0.129	0.439	CbGbCtD
Methotrexate—ALB—Crohn's disease	0.0626	1	CbGaD
Methotrexate—AOX1—Mercaptopurine—Crohn's disease	0.055	0.187	CbGbCtD
Methotrexate—ABCC4—Mercaptopurine—Crohn's disease	0.0279	0.095	CbGbCtD
Methotrexate—SLC22A8—Mercaptopurine—Crohn's disease	0.0175	0.0594	CbGbCtD
Methotrexate—SLCO1B1—Sulfasalazine—Crohn's disease	0.0154	0.0524	CbGbCtD
Methotrexate—ABCC2—Sulfasalazine—Crohn's disease	0.0135	0.0461	CbGbCtD
Methotrexate—SLCO1A2—Prednisone—Crohn's disease	0.0131	0.0444	CbGbCtD
Methotrexate—ABCG2—Sulfasalazine—Crohn's disease	0.0122	0.0416	CbGbCtD
Methotrexate—ALB—Prednisone—Crohn's disease	0.00675	0.0229	CbGbCtD
Methotrexate—ABCB1—Prednisone—Crohn's disease	0.00353	0.012	CbGbCtD
Methotrexate—ABCC2—bile—Crohn's disease	0.00186	0.0559	CbGeAlD
Methotrexate—FOLR1—mouth—Crohn's disease	0.00183	0.055	CbGeAlD
Methotrexate—SLC19A1—mouth—Crohn's disease	0.0016	0.0482	CbGeAlD
Methotrexate—FOLR1—epithelium—Crohn's disease	0.00106	0.032	CbGeAlD
Methotrexate—TYMS—Diflunisal—Mesalazine—Crohn's disease	0.000883	0.699	CbGdCrCtD
Methotrexate—FOLR1—lymphoid tissue—Crohn's disease	0.00082	0.0246	CbGeAlD
Methotrexate—SLC19A1—lymphoid tissue—Crohn's disease	0.000719	0.0216	CbGeAlD
Methotrexate—SLC19A1—digestive system—Crohn's disease	0.00071	0.0213	CbGeAlD
Methotrexate—GGH—smooth muscle tissue—Crohn's disease	0.000682	0.0205	CbGeAlD
Methotrexate—GGH—skin of body—Crohn's disease	0.000673	0.0202	CbGeAlD
Methotrexate—AOX1—gall bladder—Crohn's disease	0.000661	0.0199	CbGeAlD
Methotrexate—ABCC3—gall bladder—Crohn's disease	0.000647	0.0194	CbGeAlD
Methotrexate—GGH—mammalian vulva—Crohn's disease	0.000614	0.0184	CbGeAlD
Methotrexate—ATIC—epithelium—Crohn's disease	0.000601	0.0181	CbGeAlD
Methotrexate—FPGS—skin of body—Crohn's disease	0.000591	0.0178	CbGeAlD
Methotrexate—ATIC—smooth muscle tissue—Crohn's disease	0.00058	0.0174	CbGeAlD
Methotrexate—ATIC—skin of body—Crohn's disease	0.000572	0.0172	CbGeAlD
Methotrexate—SLC46A1—lymphoid tissue—Crohn's disease	0.000554	0.0166	CbGeAlD
Methotrexate—ALB—gall bladder—Crohn's disease	0.000552	0.0166	CbGeAlD
Methotrexate—SLC46A1—digestive system—Crohn's disease	0.000547	0.0164	CbGeAlD
Methotrexate—SLCO4C1—mammalian vulva—Crohn's disease	0.000544	0.0163	CbGeAlD
Methotrexate—FPGS—mammalian vulva—Crohn's disease	0.000539	0.0162	CbGeAlD
Methotrexate—GGH—digestive system—Crohn's disease	0.000538	0.0162	CbGeAlD
Methotrexate—FPGS—lymphoid tissue—Crohn's disease	0.000479	0.0144	CbGeAlD
Methotrexate—FPGS—digestive system—Crohn's disease	0.000473	0.0142	CbGeAlD
Methotrexate—ATIC—lymphoid tissue—Crohn's disease	0.000463	0.0139	CbGeAlD
Methotrexate—ATIC—digestive system—Crohn's disease	0.000458	0.0137	CbGeAlD
Methotrexate—SLC19A1—lymph node—Crohn's disease	0.000406	0.0122	CbGeAlD
Methotrexate—TYMS—smooth muscle tissue—Crohn's disease	0.000393	0.0118	CbGeAlD
Methotrexate—TYMS—skin of body—Crohn's disease	0.000388	0.0117	CbGeAlD
Methotrexate—SLCO3A1—mammalian vulva—Crohn's disease	0.000382	0.0115	CbGeAlD
Methotrexate—PGD—smooth muscle tissue—Crohn's disease	0.000374	0.0112	CbGeAlD
Methotrexate—SLC22A11—digestive system—Crohn's disease	0.00037	0.0111	CbGeAlD
Methotrexate—PGD—skin of body—Crohn's disease	0.000369	0.0111	CbGeAlD
Methotrexate—SLC16A1—epithelium—Crohn's disease	0.000362	0.0109	CbGeAlD
Methotrexate—SLC22A7—digestive system—Crohn's disease	0.000361	0.0108	CbGeAlD
Methotrexate—TYMS—mammalian vulva—Crohn's disease	0.000354	0.0106	CbGeAlD
Methotrexate—DHFR—mammalian vulva—Crohn's disease	0.00035	0.0105	CbGeAlD
Methotrexate—MTHFR—lymphoid tissue—Crohn's disease	0.000344	0.0103	CbGeAlD
Methotrexate—MTHFR—digestive system—Crohn's disease	0.00034	0.0102	CbGeAlD
Methotrexate—PGD—mammalian vulva—Crohn's disease	0.000337	0.0101	CbGeAlD
Methotrexate—TYMS—lymphoid tissue—Crohn's disease	0.000314	0.00944	CbGeAlD
Methotrexate—SLC46A1—lymph node—Crohn's disease	0.000312	0.00939	CbGeAlD
Methotrexate—DHFR—lymphoid tissue—Crohn's disease	0.000311	0.00934	CbGeAlD
Methotrexate—TYMS—digestive system—Crohn's disease	0.00031	0.00932	CbGeAlD
Methotrexate—GGH—lymph node—Crohn's disease	0.000307	0.00923	CbGeAlD
Methotrexate—DHFR—digestive system—Crohn's disease	0.000307	0.00923	CbGeAlD
Methotrexate—PGD—lymphoid tissue—Crohn's disease	0.000299	0.00898	CbGeAlD
Methotrexate—AOX1—mammalian vulva—Crohn's disease	0.000297	0.00891	CbGeAlD
Methotrexate—PGD—digestive system—Crohn's disease	0.000295	0.00887	CbGeAlD
Methotrexate—ABCC10—mammalian vulva—Crohn's disease	0.000289	0.00868	CbGeAlD
Methotrexate—SLC16A1—digestive system—Crohn's disease	0.000276	0.00828	CbGeAlD
Methotrexate—FPGS—lymph node—Crohn's disease	0.00027	0.00812	CbGeAlD
Methotrexate—SLCO1B1—digestive system—Crohn's disease	0.000268	0.00806	CbGeAlD
Methotrexate—ATIC—lymph node—Crohn's disease	0.000261	0.00785	CbGeAlD
Methotrexate—AOX1—digestive system—Crohn's disease	0.00026	0.00782	CbGeAlD
Methotrexate—ABCC10—lymphoid tissue—Crohn's disease	0.000256	0.0077	CbGeAlD
Methotrexate—ABCC3—digestive system—Crohn's disease	0.000255	0.00765	CbGeAlD
Methotrexate—ABCC10—digestive system—Crohn's disease	0.000253	0.00761	CbGeAlD
Methotrexate—Bone disorder—Mesalazine—Crohn's disease	0.000236	0.00328	CcSEcCtD
Methotrexate—Skin discolouration—Mesalazine—Crohn's disease	0.000236	0.00328	CcSEcCtD
Methotrexate—Pancytopenia—Mercaptopurine—Crohn's disease	0.000234	0.00325	CcSEcCtD
Methotrexate—Hepatic enzyme increased—Mesalazine—Crohn's disease	0.000225	0.00313	CcSEcCtD
Methotrexate—Aplastic anaemia—Azathioprine—Crohn's disease	0.00022	0.00305	CcSEcCtD
Methotrexate—SLCO1A2—digestive system—Crohn's disease	0.000218	0.00656	CbGeAlD
Methotrexate—SLCO1C1—lymph node—Crohn's disease	0.000217	0.00653	CbGeAlD
Methotrexate—Stomatitis—Mercaptopurine—Crohn's disease	0.000214	0.00298	CcSEcCtD
Methotrexate—Vaginal inflammation—Mesalazine—Crohn's disease	0.000213	0.00296	CcSEcCtD
Methotrexate—Neoplasm—Azathioprine—Crohn's disease	0.000212	0.00294	CcSEcCtD
Methotrexate—ABCC4—digestive system—Crohn's disease	0.00021	0.00631	CbGeAlD
Methotrexate—Melaena—Mesalazine—Crohn's disease	0.000208	0.00289	CcSEcCtD
Methotrexate—Cystitis noninfective—Mesalazine—Crohn's disease	0.000208	0.00289	CcSEcCtD
Methotrexate—Hepatobiliary disease—Mercaptopurine—Crohn's disease	0.000208	0.00289	CcSEcCtD
Methotrexate—Cystitis—Mesalazine—Crohn's disease	0.000206	0.00286	CcSEcCtD
Methotrexate—ABCC1—mammalian vulva—Crohn's disease	0.000204	0.00614	CbGeAlD
Methotrexate—Skin exfoliation—Mesalazine—Crohn's disease	0.000204	0.00283	CcSEcCtD
Methotrexate—ABCC2—digestive system—Crohn's disease	0.000203	0.00611	CbGeAlD
Methotrexate—Vaginal infection—Mesalazine—Crohn's disease	0.000201	0.0028	CcSEcCtD
Methotrexate—Osteoporosis—Prednisone—Crohn's disease	0.000201	0.0028	CcSEcCtD
Methotrexate—Aplastic anaemia—Mesalazine—Crohn's disease	0.0002	0.00278	CcSEcCtD
Methotrexate—Coma—Mesalazine—Crohn's disease	0.000195	0.00271	CcSEcCtD
Methotrexate—MTHFR—lymph node—Crohn's disease	0.000194	0.00584	CbGeAlD
Methotrexate—Fracture—Prednisone—Crohn's disease	0.000194	0.0027	CcSEcCtD
Methotrexate—Multiple fractures—Prednisone—Crohn's disease	0.000194	0.0027	CcSEcCtD
Methotrexate—Bladder pain—Mesalazine—Crohn's disease	0.000193	0.00268	CcSEcCtD
Methotrexate—Mouth ulceration—Mesalazine—Crohn's disease	0.000193	0.00268	CcSEcCtD
Methotrexate—Ecchymosis—Mesalazine—Crohn's disease	0.000193	0.00268	CcSEcCtD
Methotrexate—SLCO3A1—lymph node—Crohn's disease	0.000191	0.00574	CbGeAlD
Methotrexate—Hepatic failure—Azathioprine—Crohn's disease	0.000189	0.00263	CcSEcCtD
Methotrexate—Febrile neutropenia—Prednisone—Crohn's disease	0.000187	0.00261	CcSEcCtD
Methotrexate—Lymphadenopathy—Mesalazine—Crohn's disease	0.000181	0.00252	CcSEcCtD
Methotrexate—Immune system disorder—Mercaptopurine—Crohn's disease	0.000178	0.00248	CcSEcCtD
Methotrexate—TYMS—lymph node—Crohn's disease	0.000177	0.00532	CbGeAlD
Methotrexate—Photosensitivity—Mesalazine—Crohn's disease	0.000176	0.00245	CcSEcCtD
Methotrexate—Embolism—Prednisone—Crohn's disease	0.000176	0.00244	CcSEcCtD
Methotrexate—DHFR—lymph node—Crohn's disease	0.000176	0.00527	CbGeAlD
Methotrexate—Alopecia—Mercaptopurine—Crohn's disease	0.000174	0.00242	CcSEcCtD
Methotrexate—Hepatic failure—Mesalazine—Crohn's disease	0.000172	0.00239	CcSEcCtD
Methotrexate—Malnutrition—Mercaptopurine—Crohn's disease	0.000172	0.00239	CcSEcCtD
Methotrexate—ABCG2—mammalian vulva—Crohn's disease	0.000169	0.00508	CbGeAlD
Methotrexate—PGD—lymph node—Crohn's disease	0.000169	0.00507	CbGeAlD
Methotrexate—Renal failure acute—Mesalazine—Crohn's disease	0.000168	0.00233	CcSEcCtD
Methotrexate—Anaemia—Mercaptopurine—Crohn's disease	0.000159	0.00221	CcSEcCtD
Methotrexate—Lethargy—Mesalazine—Crohn's disease	0.000158	0.0022	CcSEcCtD
Methotrexate—SLC16A1—lymph node—Crohn's disease	0.000158	0.00473	CbGeAlD
Methotrexate—Osteoarthritis—Mesalazine—Crohn's disease	0.000155	0.00215	CcSEcCtD
Methotrexate—Leukopenia—Mercaptopurine—Crohn's disease	0.000154	0.00214	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Azathioprine—Crohn's disease	0.000153	0.00213	CcSEcCtD
Methotrexate—AOX1—lymph node—Crohn's disease	0.000149	0.00447	CbGeAlD
Methotrexate—Mood swings—Mesalazine—Crohn's disease	0.000147	0.00204	CcSEcCtD
Methotrexate—Arthralgia—Mercaptopurine—Crohn's disease	0.000146	0.00203	CcSEcCtD
Methotrexate—Fungal infection—Prednisone—Crohn's disease	0.000146	0.00203	CcSEcCtD
Methotrexate—ABCC3—lymph node—Crohn's disease	0.000145	0.00437	CbGeAlD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.000145	0.00202	CcSEcCtD
Methotrexate—ABCC10—lymph node—Crohn's disease	0.000145	0.00435	CbGeAlD
Methotrexate—Pancreatitis—Azathioprine—Crohn's disease	0.000144	0.002	CcSEcCtD
Methotrexate—Necrosis—Prednisone—Crohn's disease	0.000144	0.002	CcSEcCtD
Methotrexate—Liver function test abnormal—Mesalazine—Crohn's disease	0.000143	0.00199	CcSEcCtD
Methotrexate—Abscess—Prednisone—Crohn's disease	0.000143	0.00198	CcSEcCtD
Methotrexate—Abdominal discomfort—Azathioprine—Crohn's disease	0.000141	0.00196	CcSEcCtD
Methotrexate—Breast disorder—Mesalazine—Crohn's disease	0.00014	0.00194	CcSEcCtD
Methotrexate—Pancytopenia—Azathioprine—Crohn's disease	0.000139	0.00194	CcSEcCtD
Methotrexate—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.000137	0.00191	CcSEcCtD
Methotrexate—Petechiae—Prednisone—Crohn's disease	0.000137	0.00191	CcSEcCtD
Methotrexate—Skin disorder—Mercaptopurine—Crohn's disease	0.000136	0.00189	CcSEcCtD
Methotrexate—Asthma—Mesalazine—Crohn's disease	0.000134	0.00186	CcSEcCtD
Methotrexate—Anorexia—Mercaptopurine—Crohn's disease	0.000134	0.00186	CcSEcCtD
Methotrexate—Eosinophilia—Mesalazine—Crohn's disease	0.000132	0.00184	CcSEcCtD
Methotrexate—Pneumonia—Azathioprine—Crohn's disease	0.000132	0.00183	CcSEcCtD
Methotrexate—Pancreatitis—Mesalazine—Crohn's disease	0.000131	0.00182	CcSEcCtD
Methotrexate—Infestation—Azathioprine—Crohn's disease	0.000131	0.00182	CcSEcCtD
Methotrexate—Infestation NOS—Azathioprine—Crohn's disease	0.000131	0.00182	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.00013	0.0018	CcSEcCtD
Methotrexate—Abdominal discomfort—Mesalazine—Crohn's disease	0.000128	0.00178	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.000128	0.00178	CcSEcCtD
Methotrexate—Pancytopenia—Mesalazine—Crohn's disease	0.000127	0.00177	CcSEcCtD
Methotrexate—Dysuria—Mesalazine—Crohn's disease	0.000125	0.00174	CcSEcCtD
Methotrexate—Neutropenia—Mesalazine—Crohn's disease	0.000125	0.00174	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.000124	0.00173	CcSEcCtD
Methotrexate—ALB—lymph node—Crohn's disease	0.000124	0.00372	CbGeAlD
Methotrexate—Hepatobiliary disease—Azathioprine—Crohn's disease	0.000124	0.00172	CcSEcCtD
Methotrexate—Agranulocytosis—Azathioprine—Crohn's disease	0.000122	0.0017	CcSEcCtD
Methotrexate—Photosensitivity reaction—Mesalazine—Crohn's disease	0.000122	0.0017	CcSEcCtD
Methotrexate—Decreased appetite—Mercaptopurine—Crohn's disease	0.000122	0.00169	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000121	0.00168	CcSEcCtD
Methotrexate—ABCC4—lymph node—Crohn's disease	0.00012	0.0036	CbGeAlD
Methotrexate—Pneumonia—Mesalazine—Crohn's disease	0.00012	0.00167	CcSEcCtD
Methotrexate—Infestation—Mesalazine—Crohn's disease	0.000119	0.00166	CcSEcCtD
Methotrexate—Infestation NOS—Mesalazine—Crohn's disease	0.000119	0.00166	CcSEcCtD
Methotrexate—Ulcer—Prednisone—Crohn's disease	0.000119	0.00166	CcSEcCtD
Methotrexate—Depression—Mesalazine—Crohn's disease	0.000119	0.00165	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.000118	0.00164	CcSEcCtD
Methotrexate—Haemoglobin—Azathioprine—Crohn's disease	0.000118	0.00164	CcSEcCtD
Methotrexate—Haemorrhage—Azathioprine—Crohn's disease	0.000118	0.00163	CcSEcCtD
Methotrexate—Renal failure—Mesalazine—Crohn's disease	0.000117	0.00163	CcSEcCtD
Methotrexate—Stomatitis—Mesalazine—Crohn's disease	0.000116	0.00162	CcSEcCtD
Methotrexate—ABCC2—lymph node—Crohn's disease	0.000116	0.00349	CbGeAlD
Methotrexate—Conjunctivitis—Mesalazine—Crohn's disease	0.000116	0.00161	CcSEcCtD
Methotrexate—Vasculitis—Prednisone—Crohn's disease	0.000116	0.00161	CcSEcCtD
Methotrexate—Sweating—Mesalazine—Crohn's disease	0.000114	0.00159	CcSEcCtD
Methotrexate—Haematuria—Mesalazine—Crohn's disease	0.000114	0.00158	CcSEcCtD
Methotrexate—Hepatobiliary disease—Mesalazine—Crohn's disease	0.000113	0.00157	CcSEcCtD
Methotrexate—Epistaxis—Mesalazine—Crohn's disease	0.000112	0.00156	CcSEcCtD
Methotrexate—Agranulocytosis—Mesalazine—Crohn's disease	0.000111	0.00155	CcSEcCtD
Methotrexate—Erythema multiforme—Azathioprine—Crohn's disease	0.000111	0.00154	CcSEcCtD
Methotrexate—Body temperature increased—Mercaptopurine—Crohn's disease	0.000111	0.00154	CcSEcCtD
Methotrexate—Skin exfoliation—Prednisone—Crohn's disease	0.000108	0.0015	CcSEcCtD
Methotrexate—Haemoglobin—Mesalazine—Crohn's disease	0.000108	0.0015	CcSEcCtD
Methotrexate—Hepatitis—Mesalazine—Crohn's disease	0.000107	0.00149	CcSEcCtD
Methotrexate—Haemorrhage—Mesalazine—Crohn's disease	0.000107	0.00149	CcSEcCtD
Methotrexate—Pharyngitis—Mesalazine—Crohn's disease	0.000106	0.00148	CcSEcCtD
Methotrexate—Immune system disorder—Azathioprine—Crohn's disease	0.000106	0.00148	CcSEcCtD
Methotrexate—Mediastinal disorder—Azathioprine—Crohn's disease	0.000106	0.00147	CcSEcCtD
Methotrexate—Urinary tract disorder—Mesalazine—Crohn's disease	0.000106	0.00147	CcSEcCtD
Methotrexate—Chills—Azathioprine—Crohn's disease	0.000105	0.00147	CcSEcCtD
Methotrexate—Urethral disorder—Mesalazine—Crohn's disease	0.000105	0.00146	CcSEcCtD
Methotrexate—Alopecia—Azathioprine—Crohn's disease	0.000104	0.00144	CcSEcCtD
Methotrexate—Hypersensitivity—Mercaptopurine—Crohn's disease	0.000103	0.00144	CcSEcCtD
Methotrexate—ABCC1—lymph node—Crohn's disease	0.000102	0.00307	CbGeAlD
Methotrexate—Ecchymosis—Prednisone—Crohn's disease	0.000102	0.00142	CcSEcCtD
Methotrexate—Erythema multiforme—Mesalazine—Crohn's disease	0.000101	0.00141	CcSEcCtD
Methotrexate—Pulmonary oedema—Prednisone—Crohn's disease	0.0001	0.0014	CcSEcCtD
Methotrexate—Eye disorder—Mesalazine—Crohn's disease	0.0001	0.00139	CcSEcCtD
Methotrexate—Tinnitus—Mesalazine—Crohn's disease	9.98e-05	0.00139	CcSEcCtD
Methotrexate—Cardiac disorder—Mesalazine—Crohn's disease	9.94e-05	0.00138	CcSEcCtD
Methotrexate—Sepsis—Prednisone—Crohn's disease	9.79e-05	0.00136	CcSEcCtD
Methotrexate—Angiopathy—Mesalazine—Crohn's disease	9.71e-05	0.00135	CcSEcCtD
Methotrexate—Immune system disorder—Mesalazine—Crohn's disease	9.67e-05	0.00134	CcSEcCtD
Methotrexate—Mediastinal disorder—Mesalazine—Crohn's disease	9.65e-05	0.00134	CcSEcCtD
Methotrexate—ABCB1—epithelium—Crohn's disease	9.61e-05	0.00289	CbGeAlD
Methotrexate—Chills—Mesalazine—Crohn's disease	9.61e-05	0.00134	CcSEcCtD
Methotrexate—Diarrhoea—Mercaptopurine—Crohn's disease	9.59e-05	0.00133	CcSEcCtD
Methotrexate—Ill-defined disorder—Azathioprine—Crohn's disease	9.49e-05	0.00132	CcSEcCtD
Methotrexate—Alopecia—Mesalazine—Crohn's disease	9.46e-05	0.00132	CcSEcCtD
Methotrexate—Thrombophlebitis—Prednisone—Crohn's disease	9.46e-05	0.00131	CcSEcCtD
Methotrexate—Anaemia—Azathioprine—Crohn's disease	9.46e-05	0.00131	CcSEcCtD
Methotrexate—Diabetes mellitus—Prednisone—Crohn's disease	9.41e-05	0.00131	CcSEcCtD
Methotrexate—Mental disorder—Mesalazine—Crohn's disease	9.38e-05	0.0013	CcSEcCtD
Methotrexate—Erythema—Mesalazine—Crohn's disease	9.32e-05	0.0013	CcSEcCtD
Methotrexate—Malaise—Azathioprine—Crohn's disease	9.23e-05	0.00128	CcSEcCtD
Methotrexate—Leukopenia—Azathioprine—Crohn's disease	9.16e-05	0.00127	CcSEcCtD
Methotrexate—Dysgeusia—Mesalazine—Crohn's disease	9.13e-05	0.00127	CcSEcCtD
Methotrexate—Back pain—Mesalazine—Crohn's disease	9.01e-05	0.00125	CcSEcCtD
Methotrexate—Vomiting—Mercaptopurine—Crohn's disease	8.91e-05	0.00124	CcSEcCtD
Methotrexate—Rash—Mercaptopurine—Crohn's disease	8.84e-05	0.00123	CcSEcCtD
Methotrexate—Dermatitis—Mercaptopurine—Crohn's disease	8.83e-05	0.00123	CcSEcCtD
Methotrexate—Vision blurred—Mesalazine—Crohn's disease	8.78e-05	0.00122	CcSEcCtD
Methotrexate—Arthralgia—Azathioprine—Crohn's disease	8.71e-05	0.00121	CcSEcCtD
Methotrexate—Myalgia—Azathioprine—Crohn's disease	8.71e-05	0.00121	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	8.65e-05	0.0012	CcSEcCtD
Methotrexate—Ill-defined disorder—Mesalazine—Crohn's disease	8.65e-05	0.0012	CcSEcCtD
Methotrexate—Anaemia—Mesalazine—Crohn's disease	8.61e-05	0.0012	CcSEcCtD
Methotrexate—Discomfort—Azathioprine—Crohn's disease	8.61e-05	0.0012	CcSEcCtD
Methotrexate—ABCG2—lymph node—Crohn's disease	8.47e-05	0.00254	CbGeAlD
Methotrexate—Malaise—Mesalazine—Crohn's disease	8.4e-05	0.00117	CcSEcCtD
Methotrexate—Vertigo—Mesalazine—Crohn's disease	8.37e-05	0.00116	CcSEcCtD
Methotrexate—Lethargy—Prednisone—Crohn's disease	8.36e-05	0.00116	CcSEcCtD
Methotrexate—Leukopenia—Mesalazine—Crohn's disease	8.34e-05	0.00116	CcSEcCtD
Methotrexate—ABCB1—mammalian vulva—Crohn's disease	8.34e-05	0.0025	CbGeAlD
Methotrexate—Nausea—Mercaptopurine—Crohn's disease	8.32e-05	0.00116	CcSEcCtD
Methotrexate—Infection—Azathioprine—Crohn's disease	8.3e-05	0.00115	CcSEcCtD
Methotrexate—Osteoarthritis—Prednisone—Crohn's disease	8.19e-05	0.00114	CcSEcCtD
Methotrexate—Thrombocytopenia—Azathioprine—Crohn's disease	8.18e-05	0.00114	CcSEcCtD
Methotrexate—Cough—Mesalazine—Crohn's disease	8.13e-05	0.00113	CcSEcCtD
Methotrexate—Skin disorder—Azathioprine—Crohn's disease	8.11e-05	0.00113	CcSEcCtD
Methotrexate—Chest pain—Mesalazine—Crohn's disease	7.93e-05	0.0011	CcSEcCtD
Methotrexate—Myalgia—Mesalazine—Crohn's disease	7.93e-05	0.0011	CcSEcCtD
Methotrexate—Arthralgia—Mesalazine—Crohn's disease	7.93e-05	0.0011	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	7.88e-05	0.0011	CcSEcCtD
Methotrexate—Discomfort—Mesalazine—Crohn's disease	7.84e-05	0.00109	CcSEcCtD
Methotrexate—Irritability—Prednisone—Crohn's disease	7.82e-05	0.00109	CcSEcCtD
Methotrexate—Hypotension—Azathioprine—Crohn's disease	7.8e-05	0.00108	CcSEcCtD
Methotrexate—Mood swings—Prednisone—Crohn's disease	7.76e-05	0.00108	CcSEcCtD
Methotrexate—Confusional state—Mesalazine—Crohn's disease	7.67e-05	0.00107	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Azathioprine—Crohn's disease	7.61e-05	0.00106	CcSEcCtD
Methotrexate—Anaphylactic shock—Mesalazine—Crohn's disease	7.61e-05	0.00106	CcSEcCtD
Methotrexate—Infection—Mesalazine—Crohn's disease	7.56e-05	0.00105	CcSEcCtD
Methotrexate—Nervous system disorder—Mesalazine—Crohn's disease	7.46e-05	0.00104	CcSEcCtD
Methotrexate—Thrombocytopenia—Mesalazine—Crohn's disease	7.45e-05	0.00104	CcSEcCtD
Methotrexate—ABCB1—lymphoid tissue—Crohn's disease	7.4e-05	0.00222	CbGeAlD
Methotrexate—Skin disorder—Mesalazine—Crohn's disease	7.39e-05	0.00103	CcSEcCtD
Methotrexate—Hyperhidrosis—Mesalazine—Crohn's disease	7.35e-05	0.00102	CcSEcCtD
Methotrexate—ABCB1—digestive system—Crohn's disease	7.31e-05	0.0022	CbGeAlD
Methotrexate—Anorexia—Mesalazine—Crohn's disease	7.25e-05	0.00101	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Azathioprine—Crohn's disease	7.21e-05	0.001	CcSEcCtD
Methotrexate—Hypotension—Mesalazine—Crohn's disease	7.11e-05	0.000988	CcSEcCtD
Methotrexate—TYMS—Clobetasol propionate—Prednisone—Crohn's disease	7.02e-05	0.0556	CbGdCrCtD
Methotrexate—Pancreatitis—Prednisone—Crohn's disease	6.94e-05	0.000965	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Mesalazine—Crohn's disease	6.93e-05	0.000963	CcSEcCtD
Methotrexate—TYMS—Flunisolide—Prednisone—Crohn's disease	6.92e-05	0.0549	CbGdCrCtD
Methotrexate—Feeling abnormal—Azathioprine—Crohn's disease	6.88e-05	0.000957	CcSEcCtD
Methotrexate—Insomnia—Mesalazine—Crohn's disease	6.88e-05	0.000956	CcSEcCtD
Methotrexate—TYMS—Triamcinolone—Prednisone—Crohn's disease	6.85e-05	0.0543	CbGdCrCtD
Methotrexate—Paraesthesia—Mesalazine—Crohn's disease	6.83e-05	0.000949	CcSEcCtD
Methotrexate—Gastrointestinal pain—Azathioprine—Crohn's disease	6.83e-05	0.000949	CcSEcCtD
Methotrexate—Dyspnoea—Mesalazine—Crohn's disease	6.78e-05	0.000943	CcSEcCtD
Methotrexate—Somnolence—Mesalazine—Crohn's disease	6.76e-05	0.00094	CcSEcCtD
Methotrexate—Dyspepsia—Mesalazine—Crohn's disease	6.7e-05	0.000931	CcSEcCtD
Methotrexate—Neutropenia—Prednisone—Crohn's disease	6.62e-05	0.00092	CcSEcCtD
Methotrexate—Decreased appetite—Mesalazine—Crohn's disease	6.61e-05	0.000919	CcSEcCtD
Methotrexate—Abdominal pain—Azathioprine—Crohn's disease	6.6e-05	0.000918	CcSEcCtD
Methotrexate—Body temperature increased—Azathioprine—Crohn's disease	6.6e-05	0.000918	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Mesalazine—Crohn's disease	6.57e-05	0.000913	CcSEcCtD
Methotrexate—Fatigue—Mesalazine—Crohn's disease	6.56e-05	0.000912	CcSEcCtD
Methotrexate—Erectile dysfunction—Prednisone—Crohn's disease	6.52e-05	0.000906	CcSEcCtD
Methotrexate—Pain—Mesalazine—Crohn's disease	6.5e-05	0.000904	CcSEcCtD
Methotrexate—TYMS—Diflorasone—Prednisone—Crohn's disease	6.32e-05	0.05	CbGdCrCtD
Methotrexate—Depression—Prednisone—Crohn's disease	6.29e-05	0.000875	CcSEcCtD
Methotrexate—Feeling abnormal—Mesalazine—Crohn's disease	6.27e-05	0.000871	CcSEcCtD
Methotrexate—Gastrointestinal pain—Mesalazine—Crohn's disease	6.22e-05	0.000865	CcSEcCtD
Methotrexate—Hypersensitivity—Azathioprine—Crohn's disease	6.15e-05	0.000855	CcSEcCtD
Methotrexate—Urticaria—Mesalazine—Crohn's disease	6.04e-05	0.00084	CcSEcCtD
Methotrexate—Abdominal pain—Mesalazine—Crohn's disease	6.01e-05	0.000836	CcSEcCtD
Methotrexate—Body temperature increased—Mesalazine—Crohn's disease	6.01e-05	0.000836	CcSEcCtD
Methotrexate—Diarrhoea—Azathioprine—Crohn's disease	5.71e-05	0.000794	CcSEcCtD
Methotrexate—Haemoglobin—Prednisone—Crohn's disease	5.69e-05	0.000791	CcSEcCtD
Methotrexate—Haemorrhage—Prednisone—Crohn's disease	5.66e-05	0.000787	CcSEcCtD
Methotrexate—Hypersensitivity—Mesalazine—Crohn's disease	5.6e-05	0.000779	CcSEcCtD
Methotrexate—TYMS—Budesonide—Prednisone—Crohn's disease	5.54e-05	0.0439	CbGdCrCtD
Methotrexate—Dizziness—Azathioprine—Crohn's disease	5.52e-05	0.000768	CcSEcCtD
Methotrexate—Asthenia—Mesalazine—Crohn's disease	5.46e-05	0.000759	CcSEcCtD
Methotrexate—Pruritus—Mesalazine—Crohn's disease	5.38e-05	0.000748	CcSEcCtD
Methotrexate—Vomiting—Azathioprine—Crohn's disease	5.31e-05	0.000738	CcSEcCtD
Methotrexate—TYMS—Danazol—Prednisone—Crohn's disease	5.31e-05	0.042	CbGdCrCtD
Methotrexate—Eye disorder—Prednisone—Crohn's disease	5.29e-05	0.000736	CcSEcCtD
Methotrexate—Rash—Azathioprine—Crohn's disease	5.26e-05	0.000732	CcSEcCtD
Methotrexate—Dermatitis—Azathioprine—Crohn's disease	5.26e-05	0.000731	CcSEcCtD
Methotrexate—Headache—Azathioprine—Crohn's disease	5.23e-05	0.000727	CcSEcCtD
Methotrexate—Diarrhoea—Mesalazine—Crohn's disease	5.2e-05	0.000723	CcSEcCtD
Methotrexate—Angiopathy—Prednisone—Crohn's disease	5.14e-05	0.000714	CcSEcCtD
Methotrexate—Immune system disorder—Prednisone—Crohn's disease	5.12e-05	0.000711	CcSEcCtD
Methotrexate—Dizziness—Mesalazine—Crohn's disease	5.03e-05	0.000699	CcSEcCtD
Methotrexate—Alopecia—Prednisone—Crohn's disease	5.01e-05	0.000696	CcSEcCtD
Methotrexate—Mental disorder—Prednisone—Crohn's disease	4.96e-05	0.00069	CcSEcCtD
Methotrexate—Nausea—Azathioprine—Crohn's disease	4.96e-05	0.00069	CcSEcCtD
Methotrexate—Malnutrition—Prednisone—Crohn's disease	4.93e-05	0.000685	CcSEcCtD
Methotrexate—Erythema—Prednisone—Crohn's disease	4.93e-05	0.000685	CcSEcCtD
Methotrexate—Vomiting—Mesalazine—Crohn's disease	4.84e-05	0.000672	CcSEcCtD
Methotrexate—Rash—Mesalazine—Crohn's disease	4.8e-05	0.000667	CcSEcCtD
Methotrexate—Dermatitis—Mesalazine—Crohn's disease	4.79e-05	0.000666	CcSEcCtD
Methotrexate—Headache—Mesalazine—Crohn's disease	4.76e-05	0.000662	CcSEcCtD
Methotrexate—Vision blurred—Prednisone—Crohn's disease	4.65e-05	0.000646	CcSEcCtD
Methotrexate—Ill-defined disorder—Prednisone—Crohn's disease	4.58e-05	0.000636	CcSEcCtD
Methotrexate—Anaemia—Prednisone—Crohn's disease	4.56e-05	0.000634	CcSEcCtD
Methotrexate—Nausea—Mesalazine—Crohn's disease	4.52e-05	0.000628	CcSEcCtD
Methotrexate—Malaise—Prednisone—Crohn's disease	4.45e-05	0.000618	CcSEcCtD
Methotrexate—Vertigo—Prednisone—Crohn's disease	4.43e-05	0.000616	CcSEcCtD
Methotrexate—Convulsion—Prednisone—Crohn's disease	4.27e-05	0.000594	CcSEcCtD
Methotrexate—Arthralgia—Prednisone—Crohn's disease	4.2e-05	0.000584	CcSEcCtD
Methotrexate—Myalgia—Prednisone—Crohn's disease	4.2e-05	0.000584	CcSEcCtD
Methotrexate—ABCB1—lymph node—Crohn's disease	4.18e-05	0.00125	CbGeAlD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	4.17e-05	0.00058	CcSEcCtD
Methotrexate—Discomfort—Prednisone—Crohn's disease	4.15e-05	0.000577	CcSEcCtD
Methotrexate—Anaphylactic shock—Prednisone—Crohn's disease	4.02e-05	0.000559	CcSEcCtD
Methotrexate—Infection—Prednisone—Crohn's disease	4e-05	0.000556	CcSEcCtD
Methotrexate—Nervous system disorder—Prednisone—Crohn's disease	3.95e-05	0.000549	CcSEcCtD
Methotrexate—Skin disorder—Prednisone—Crohn's disease	3.91e-05	0.000543	CcSEcCtD
Methotrexate—Hyperhidrosis—Prednisone—Crohn's disease	3.89e-05	0.000541	CcSEcCtD
Methotrexate—Anorexia—Prednisone—Crohn's disease	3.84e-05	0.000533	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Prednisone—Crohn's disease	3.67e-05	0.00051	CcSEcCtD
Methotrexate—Insomnia—Prednisone—Crohn's disease	3.64e-05	0.000506	CcSEcCtD
Methotrexate—Paraesthesia—Prednisone—Crohn's disease	3.61e-05	0.000502	CcSEcCtD
Methotrexate—Dyspepsia—Prednisone—Crohn's disease	3.54e-05	0.000492	CcSEcCtD
Methotrexate—Decreased appetite—Prednisone—Crohn's disease	3.5e-05	0.000486	CcSEcCtD
Methotrexate—Fatigue—Prednisone—Crohn's disease	3.47e-05	0.000482	CcSEcCtD
Methotrexate—Feeling abnormal—Prednisone—Crohn's disease	3.32e-05	0.000461	CcSEcCtD
Methotrexate—Gastrointestinal pain—Prednisone—Crohn's disease	3.29e-05	0.000457	CcSEcCtD
Methotrexate—Urticaria—Prednisone—Crohn's disease	3.2e-05	0.000444	CcSEcCtD
Methotrexate—Body temperature increased—Prednisone—Crohn's disease	3.18e-05	0.000442	CcSEcCtD
Methotrexate—Abdominal pain—Prednisone—Crohn's disease	3.18e-05	0.000442	CcSEcCtD
Methotrexate—Hypersensitivity—Prednisone—Crohn's disease	2.96e-05	0.000412	CcSEcCtD
Methotrexate—Asthenia—Prednisone—Crohn's disease	2.89e-05	0.000401	CcSEcCtD
Methotrexate—Pruritus—Prednisone—Crohn's disease	2.85e-05	0.000396	CcSEcCtD
Methotrexate—Diarrhoea—Prednisone—Crohn's disease	2.75e-05	0.000383	CcSEcCtD
Methotrexate—Dizziness—Prednisone—Crohn's disease	2.66e-05	0.00037	CcSEcCtD
Methotrexate—Vomiting—Prednisone—Crohn's disease	2.56e-05	0.000356	CcSEcCtD
Methotrexate—Rash—Prednisone—Crohn's disease	2.54e-05	0.000353	CcSEcCtD
Methotrexate—Dermatitis—Prednisone—Crohn's disease	2.54e-05	0.000352	CcSEcCtD
Methotrexate—Headache—Prednisone—Crohn's disease	2.52e-05	0.00035	CcSEcCtD
Methotrexate—Nausea—Prednisone—Crohn's disease	2.39e-05	0.000332	CcSEcCtD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—GCKR—Crohn's disease	1.75e-05	0.000411	CbGpPWpGaD
Methotrexate—SLCO4C1—Transmembrane transport of small molecules—ALB—Crohn's disease	1.75e-05	0.00041	CbGpPWpGaD
Methotrexate—ALB—SLC-mediated transmembrane transport—SLC11A1—Crohn's disease	1.74e-05	0.000408	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—GPX4—Crohn's disease	1.74e-05	0.000407	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—MTMR3—Crohn's disease	1.74e-05	0.000407	CbGpPWpGaD
Methotrexate—SLC22A7—SLC-mediated transmembrane transport—ALB—Crohn's disease	1.72e-05	0.000403	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—GCKR—Crohn's disease	1.72e-05	0.000403	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—IFNG—Crohn's disease	1.72e-05	0.000402	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	1.7e-05	0.000399	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—FADS1—Crohn's disease	1.69e-05	0.000396	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—GCKR—Crohn's disease	1.68e-05	0.000393	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	1.65e-05	0.000387	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—ITGA4—Crohn's disease	1.65e-05	0.000386	CbGpPWpGaD
Methotrexate—SLCO1B3—SLC-mediated transmembrane transport—ALB—Crohn's disease	1.64e-05	0.000383	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	1.63e-05	0.000382	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—GCKR—Crohn's disease	1.62e-05	0.00038	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—SMAD3—Crohn's disease	1.62e-05	0.000379	CbGpPWpGaD
Methotrexate—DHFR—Disease—SLC11A1—Crohn's disease	1.61e-05	0.000378	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—IL3—Crohn's disease	1.61e-05	0.000377	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PLA2G4F—Crohn's disease	1.6e-05	0.000376	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—TYK2—Crohn's disease	1.59e-05	0.000373	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—GPX4—Crohn's disease	1.58e-05	0.00037	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—ALB—Crohn's disease	1.58e-05	0.00037	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—MTMR3—Crohn's disease	1.57e-05	0.000367	CbGpPWpGaD
Methotrexate—MTHFR—Disease—RBX1—Crohn's disease	1.56e-05	0.000364	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HSPA1B—Crohn's disease	1.56e-05	0.000364	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—RASGRP1—Crohn's disease	1.56e-05	0.000364	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	1.55e-05	0.000363	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—FADS1—Crohn's disease	1.54e-05	0.00036	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—IL1B—Crohn's disease	1.53e-05	0.000358	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—GCKR—Crohn's disease	1.53e-05	0.000358	CbGpPWpGaD
Methotrexate—AOX1—Disease—RBX1—Crohn's disease	1.52e-05	0.000356	CbGpPWpGaD
Methotrexate—AOX1—Disease—HSPA1B—Crohn's disease	1.52e-05	0.000356	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—JAK2—Crohn's disease	1.52e-05	0.000356	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—IL2RA—Crohn's disease	1.51e-05	0.000354	CbGpPWpGaD
Methotrexate—ABCC1—Disease—RSPO3—Crohn's disease	1.51e-05	0.000353	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	1.5e-05	0.00035	CbGpPWpGaD
Methotrexate—PGD—Disease—SMAD3—Crohn's disease	1.48e-05	0.000346	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—FADS1—Crohn's disease	1.47e-05	0.000345	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	1.47e-05	0.000344	CbGpPWpGaD
Methotrexate—SLCO1C1—Transmembrane transport of small molecules—ALB—Crohn's disease	1.47e-05	0.000344	CbGpPWpGaD
Methotrexate—SLC22A8—SLC-mediated transmembrane transport—ALB—Crohn's disease	1.45e-05	0.000339	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PLA2G4F—Crohn's disease	1.44e-05	0.000338	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—GPX4—Crohn's disease	1.44e-05	0.000337	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—CD4—Crohn's disease	1.44e-05	0.000337	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	1.44e-05	0.000336	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—PTGS2—Crohn's disease	1.43e-05	0.000335	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SEL1L—Crohn's disease	1.43e-05	0.000334	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	1.42e-05	0.000333	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	1.42e-05	0.000333	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—IL3—Crohn's disease	1.41e-05	0.000331	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—GCKR—Crohn's disease	1.39e-05	0.000326	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—Crohn's disease	1.39e-05	0.000326	CbGpPWpGaD
Methotrexate—DHFR—Disease—RBX1—Crohn's disease	1.38e-05	0.000324	CbGpPWpGaD
Methotrexate—DHFR—Disease—HSPA1B—Crohn's disease	1.38e-05	0.000324	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—GPX4—Crohn's disease	1.38e-05	0.000323	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PLA2G4F—Crohn's disease	1.37e-05	0.000321	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—ALB—Crohn's disease	1.37e-05	0.000321	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—RASGRP1—Crohn's disease	1.37e-05	0.00032	CbGpPWpGaD
Methotrexate—ALB—Vitamin B12 Metabolism—TNF—Crohn's disease	1.36e-05	0.00032	CbGpPWpGaD
Methotrexate—MTHFR—Disease—UBE2D1—Crohn's disease	1.36e-05	0.00032	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—MTMR3—Crohn's disease	1.36e-05	0.000319	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—IFNG—Crohn's disease	1.36e-05	0.000319	CbGpPWpGaD
Methotrexate—FPGS—Disease—TYK2—Crohn's disease	1.35e-05	0.000317	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—FADS1—Crohn's disease	1.35e-05	0.000317	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	1.35e-05	0.000316	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—GCKR—Crohn's disease	1.33e-05	0.000312	CbGpPWpGaD
Methotrexate—AOX1—Disease—UBE2D1—Crohn's disease	1.33e-05	0.000312	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—PTGS2—Crohn's disease	1.31e-05	0.000306	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—IFNG—Crohn's disease	1.3e-05	0.000305	CbGpPWpGaD
Methotrexate—FPGS—Disease—JAK2—Crohn's disease	1.29e-05	0.000303	CbGpPWpGaD
Methotrexate—SLCO1A2—SLC-mediated transmembrane transport—ALB—Crohn's disease	1.29e-05	0.000301	CbGpPWpGaD
Methotrexate—ABCC1—Disease—LTF—Crohn's disease	1.28e-05	0.0003	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PLA2G4F—Crohn's disease	1.27e-05	0.000297	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—GPX4—Crohn's disease	1.27e-05	0.000297	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	1.25e-05	0.000292	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	1.25e-05	0.000292	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—MTMR3—Crohn's disease	1.23e-05	0.000287	CbGpPWpGaD
Methotrexate—FPGS—Disease—CD4—Crohn's disease	1.23e-05	0.000287	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—GCKR—Crohn's disease	1.22e-05	0.000286	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—FADS1—Crohn's disease	1.22e-05	0.000286	CbGpPWpGaD
Methotrexate—FPGS—Disease—PTGS2—Crohn's disease	1.22e-05	0.000285	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—IL1B—Crohn's disease	1.22e-05	0.000285	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—F5—Crohn's disease	1.21e-05	0.000284	CbGpPWpGaD
Methotrexate—DHFR—Disease—UBE2D1—Crohn's disease	1.21e-05	0.000284	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—CXCL8—Crohn's disease	1.21e-05	0.000283	CbGpPWpGaD
Methotrexate—SLC22A6—SLC-mediated transmembrane transport—ALB—Crohn's disease	1.21e-05	0.000283	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—PTGS2—Crohn's disease	1.2e-05	0.00028	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—MTMR3—Crohn's disease	1.17e-05	0.000273	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	1.17e-05	0.000273	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—ALB—Crohn's disease	1.16e-05	0.000273	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—ALB—Crohn's disease	1.16e-05	0.000273	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—IL1B—Crohn's disease	1.16e-05	0.000272	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—GPX4—Crohn's disease	1.14e-05	0.000268	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—IL2RA—Crohn's disease	1.13e-05	0.000264	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—STAT3—Crohn's disease	1.12e-05	0.000261	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—TNF—Crohn's disease	1.11e-05	0.00026	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—GCKR—Crohn's disease	1.1e-05	0.000258	CbGpPWpGaD
Methotrexate—ALB—Vitamin B12 Metabolism—IL6—Crohn's disease	1.1e-05	0.000258	CbGpPWpGaD
Methotrexate—SLCO1B1—SLC-mediated transmembrane transport—ALB—Crohn's disease	1.1e-05	0.000257	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—ALB—Crohn's disease	1.09e-05	0.000256	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	1.09e-05	0.000256	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—MTMR3—Crohn's disease	1.08e-05	0.000253	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—FADS1—Crohn's disease	1.06e-05	0.000249	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—TYK2—Crohn's disease	1.06e-05	0.000247	CbGpPWpGaD
Methotrexate—TYMS—Circadian rythm related genes—IL6—Crohn's disease	1.04e-05	0.000244	CbGpPWpGaD
Methotrexate—ABCC1—Disease—GCKR—Crohn's disease	1.03e-05	0.000242	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—PTGS2—Crohn's disease	1.02e-05	0.000238	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—PTGS2—Crohn's disease	1.02e-05	0.000238	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—JAK2—Crohn's disease	1.02e-05	0.000238	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—JAK2—Crohn's disease	1.01e-05	0.000236	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—GCKR—Crohn's disease	1e-05	0.000235	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GPX4—Crohn's disease	9.95e-06	0.000233	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—IL2RA—Crohn's disease	9.89e-06	0.000232	CbGpPWpGaD
Methotrexate—MTHFR—Disease—SMAD3—Crohn's disease	9.76e-06	0.000229	CbGpPWpGaD
Methotrexate—PGD—Disease—TYK2—Crohn's disease	9.65e-06	0.000226	CbGpPWpGaD
Methotrexate—SLC22A11—Transmembrane transport of small molecules—ALB—Crohn's disease	9.64e-06	0.000226	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GCKR—Crohn's disease	9.61e-06	0.000225	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—FADS1—Crohn's disease	9.56e-06	0.000224	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—CD4—Crohn's disease	9.55e-06	0.000223	CbGpPWpGaD
Methotrexate—AOX1—Disease—SMAD3—Crohn's disease	9.54e-06	0.000223	CbGpPWpGaD
Methotrexate—FPGS—Disease—STAT3—Crohn's disease	9.49e-06	0.000222	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—PTGS2—Crohn's disease	9.48e-06	0.000222	CbGpPWpGaD
Methotrexate—SLC16A1—Transmembrane transport of small molecules—ALB—Crohn's disease	9.46e-06	0.000221	CbGpPWpGaD
Methotrexate—PGD—Disease—JAK2—Crohn's disease	9.21e-06	0.000216	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SLC11A1—Crohn's disease	9.13e-06	0.000214	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—FADS1—Crohn's disease	9.09e-06	0.000213	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—ALB—Crohn's disease	9.07e-06	0.000212	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—IL6—Crohn's disease	8.96e-06	0.00021	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GPX4—Crohn's disease	8.95e-06	0.00021	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	8.86e-06	0.000208	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—TNF—Crohn's disease	8.82e-06	0.000207	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—GCKR—Crohn's disease	8.78e-06	0.000206	CbGpPWpGaD
Methotrexate—SLC22A7—Transmembrane transport of small molecules—ALB—Crohn's disease	8.75e-06	0.000205	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	8.74e-06	0.000205	CbGpPWpGaD
Methotrexate—PGD—Disease—CD4—Crohn's disease	8.73e-06	0.000204	CbGpPWpGaD
Methotrexate—DHFR—Disease—SMAD3—Crohn's disease	8.68e-06	0.000203	CbGpPWpGaD
Methotrexate—PGD—Disease—PTGS2—Crohn's disease	8.67e-06	0.000203	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GCKR—Crohn's disease	8.65e-06	0.000202	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GPX4—Crohn's disease	8.51e-06	0.000199	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—TNF—Crohn's disease	8.43e-06	0.000197	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—FADS1—Crohn's disease	8.41e-06	0.000197	CbGpPWpGaD
Methotrexate—SLCO1B3—Transmembrane transport of small molecules—ALB—Crohn's disease	8.31e-06	0.000195	CbGpPWpGaD
Methotrexate—PGD—Metabolism—ALB—Crohn's disease	8.3e-06	0.000194	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GCKR—Crohn's disease	8.22e-06	0.000192	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—ALB—Crohn's disease	8.15e-06	0.000191	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PTGS2—Crohn's disease	7.94e-06	0.000186	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	7.89e-06	0.000185	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GPX4—Crohn's disease	7.88e-06	0.000184	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PLA2G4F—Crohn's disease	7.84e-06	0.000184	CbGpPWpGaD
Methotrexate—ABCC1—Disease—RBX1—Crohn's disease	7.83e-06	0.000183	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HSPA1B—Crohn's disease	7.83e-06	0.000183	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—IL6—Crohn's disease	7.79e-06	0.000182	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	7.77e-06	0.000182	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	7.65e-06	0.000179	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GCKR—Crohn's disease	7.61e-06	0.000178	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—JAK2—Crohn's disease	7.57e-06	0.000177	CbGpPWpGaD
Methotrexate—ABCC3—Transmembrane transport of small molecules—ALB—Crohn's disease	7.5e-06	0.000176	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—ITGA4—Crohn's disease	7.46e-06	0.000175	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—STAT3—Crohn's disease	7.39e-06	0.000173	CbGpPWpGaD
Methotrexate—SLC22A8—Transmembrane transport of small molecules—ALB—Crohn's disease	7.35e-06	0.000172	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IL3—Crohn's disease	7.28e-06	0.00017	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PTGS2—Crohn's disease	7.26e-06	0.00017	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—IL6—Crohn's disease	7.12e-06	0.000167	CbGpPWpGaD
Methotrexate—ABCC4—Transmembrane transport of small molecules—ALB—Crohn's disease	7.05e-06	0.000165	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—RASGRP1—Crohn's disease	7.04e-06	0.000165	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	6.9e-06	0.000162	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	6.87e-06	0.000161	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PLA2G4F—Crohn's disease	6.87e-06	0.000161	CbGpPWpGaD
Methotrexate—ABCC1—Disease—UBE2D1—Crohn's disease	6.86e-06	0.000161	CbGpPWpGaD
Methotrexate—PGD—Disease—STAT3—Crohn's disease	6.76e-06	0.000158	CbGpPWpGaD
Methotrexate—ALB—Metabolism—MTMR3—Crohn's disease	6.66e-06	0.000156	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	6.65e-06	0.000156	CbGpPWpGaD
Methotrexate—FPGS—Disease—IL6—Crohn's disease	6.63e-06	0.000155	CbGpPWpGaD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—ALB—Crohn's disease	6.53e-06	0.000153	CbGpPWpGaD
Methotrexate—MTHFR—Disease—TYK2—Crohn's disease	6.37e-06	0.000149	CbGpPWpGaD
Methotrexate—AOX1—Disease—TYK2—Crohn's disease	6.22e-06	0.000146	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	6.18e-06	0.000145	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	6.16e-06	0.000144	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—ALB—Crohn's disease	6.14e-06	0.000144	CbGpPWpGaD
Methotrexate—MTHFR—Disease—JAK2—Crohn's disease	6.08e-06	0.000142	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	6.01e-06	0.000141	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—ALB—Crohn's disease	5.95e-06	0.000139	CbGpPWpGaD
Methotrexate—AOX1—Disease—JAK2—Crohn's disease	5.93e-06	0.000139	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—ALB—Crohn's disease	5.88e-06	0.000138	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	5.87e-06	0.000138	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—MTMR3—Crohn's disease	5.84e-06	0.000137	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CD4—Crohn's disease	5.76e-06	0.000135	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTGS2—Crohn's disease	5.72e-06	0.000134	CbGpPWpGaD
Methotrexate—DHFR—Disease—TYK2—Crohn's disease	5.66e-06	0.000133	CbGpPWpGaD
Methotrexate—AOX1—Disease—CD4—Crohn's disease	5.63e-06	0.000132	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—ALB—Crohn's disease	5.58e-06	0.000131	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTGS2—Crohn's disease	5.58e-06	0.000131	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—ALB—Crohn's disease	5.47e-06	0.000128	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	5.41e-06	0.000127	CbGpPWpGaD
Methotrexate—DHFR—Disease—JAK2—Crohn's disease	5.4e-06	0.000126	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—ALB—Crohn's disease	5.35e-06	0.000125	CbGpPWpGaD
Methotrexate—ALB—Metabolism—FADS1—Crohn's disease	5.19e-06	0.000122	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—ALB—Crohn's disease	5.17e-06	0.000121	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—IL6—Crohn's disease	5.16e-06	0.000121	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	5.14e-06	0.00012	CbGpPWpGaD
Methotrexate—DHFR—Disease—CD4—Crohn's disease	5.12e-06	0.00012	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IL2RA—Crohn's disease	5.1e-06	0.000119	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTGS2—Crohn's disease	5.08e-06	0.000119	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SMAD3—Crohn's disease	4.91e-06	0.000115	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—ALB—Crohn's disease	4.86e-06	0.000114	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GPX4—Crohn's disease	4.86e-06	0.000114	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTGS2—Crohn's disease	4.79e-06	0.000112	CbGpPWpGaD
Methotrexate—PGD—Disease—IL6—Crohn's disease	4.72e-06	0.000111	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GCKR—Crohn's disease	4.7e-06	0.00011	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTGS2—Crohn's disease	4.68e-06	0.00011	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—FADS1—Crohn's disease	4.55e-06	0.000107	CbGpPWpGaD
Methotrexate—MTHFR—Disease—STAT3—Crohn's disease	4.46e-06	0.000104	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—ALB—Crohn's disease	4.43e-06	0.000104	CbGpPWpGaD
Methotrexate—AOX1—Disease—STAT3—Crohn's disease	4.36e-06	0.000102	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GPX4—Crohn's disease	4.26e-06	9.97e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTGS2—Crohn's disease	4.25e-06	9.96e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—ALB—Crohn's disease	4.24e-06	9.94e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	4.16e-06	9.74e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GCKR—Crohn's disease	4.11e-06	9.63e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—STAT3—Crohn's disease	3.96e-06	9.28e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ALB—Crohn's disease	3.89e-06	9.12e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTGS2—Crohn's disease	3.88e-06	9.07e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTGS2—Crohn's disease	3.71e-06	8.69e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ALB—Crohn's disease	3.51e-06	8.22e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—JAK2—Crohn's disease	3.43e-06	8.02e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTGS2—Crohn's disease	3.41e-06	7.97e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TYK2—Crohn's disease	3.2e-06	7.5e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—IL6—Crohn's disease	3.11e-06	7.29e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTGS2—Crohn's disease	3.07e-06	7.2e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ALB—Crohn's disease	3.06e-06	7.16e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—JAK2—Crohn's disease	3.06e-06	7.15e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—IL6—Crohn's disease	3.04e-06	7.12e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	2.94e-06	6.87e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CD4—Crohn's disease	2.9e-06	6.78e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTGS2—Crohn's disease	2.88e-06	6.73e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—ALB—Crohn's disease	2.8e-06	6.55e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—IL6—Crohn's disease	2.77e-06	6.48e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ALB—Crohn's disease	2.75e-06	6.44e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTGS2—Crohn's disease	2.68e-06	6.27e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ALB—Crohn's disease	2.62e-06	6.12e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ALB—Crohn's disease	2.42e-06	5.67e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTGS2—Crohn's disease	2.41e-06	5.64e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTGS2—Crohn's disease	2.29e-06	5.36e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—STAT3—Crohn's disease	2.24e-06	5.25e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS2—Crohn's disease	2.12e-06	4.96e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IL6—Crohn's disease	1.57e-06	3.67e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALB—Crohn's disease	1.31e-06	3.07e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS2—Crohn's disease	1.31e-06	3.06e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS2—Crohn's disease	1.15e-06	2.68e-05	CbGpPWpGaD
